Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
InPedILD-ON long-term open-label nintedanib extension in pediatric fibrosing ILD
NL-OMON54130Phase 3Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nintedanib in pulmonary fibrosis (PF), sponsored by Boehringer Ingelheim. Primary endpoint: Incidence of treatment-emergent adverse events. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
nintedanib
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NL-OMON54130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54130.